Mevion’s existing investors include Caxton Heath Life Sciences, Venrock and CHL Medical Partners.

Mevion will use the amount to accelerate the manufacturing and worldwide deployment of its MEVION S250 proton therapy system.

Proton beam radiation therapy permits the target dose precisely by complete proton absorption at predictable tissue depth, with out any harm to sensitive structures.

Mevion Medical Systems CEO Joseph Jachinowski said they welcome the new endorsement by ProQuest Investments and the continuing support of their existing financial partners.

"With delivery of our first system complete and with two additional systems now under installation, this investment will support the growing demand for our innovative technology," Jachinowski said.